CORT Corcept Therapeutics Inc

Price (delayed)

$28.14

Market cap

$3.27B

P/E Ratio

29.62

Dividend/share

N/A

EPS

$0.95

Enterprise value

$3.24B

Sector: Healthcare
Industry: Biotechnology

Highlights

The company's equity rose by 46% YoY and by 8% QoQ
The quick ratio is up by 34% year-on-year and by 3.4% since the previous quarter
The P/E is 87% more than the last 4 quarters average of 15.8 but 56% less than the 5-year quarterly average of 67.7
CORT's net income is up by 26% YoY but it is down by 4.1% QoQ

Key stats

What are the main financial stats of CORT
Market
Shares outstanding
116.17M
Market cap
$3.27B
Enterprise value
$3.24B
Valuations
Price to earnings (P/E)
29.62
Price to book (P/B)
6.64
Price to sales (P/S)
9.15
EV/EBIT
24.43
EV/EBITDA
24.02
EV/Sales
9.1
Earnings
Revenue
$356.03M
EBIT
$132.71M
EBITDA
$134.94M
Free cash flow
$164.41M
Per share
EPS
$0.95
Free cash flow per share
$1.42
Book value per share
$4.24
Revenue per share
$3.08
TBVPS
$4.62
Balance sheet
Total assets
$534.13M
Total liabilities
$44.45M
Debt
$3.03M
Equity
$489.68M
Working capital
$420.45M
Liquidity
Debt to equity
0.01
Current ratio
10.77
Quick ratio
10.47
Net debt/EBITDA
-0.2
Margins
EBITDA margin
37.9%
Gross margin
98.4%
Net margin
30.7%
Operating margin
37.3%
Efficiency
Return on assets
23.2%
Return on equity
25.4%
Return on invested capital
34.5%
Return on capital employed
27%
Return on sales
37.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CORT stock price

How has the Corcept Therapeutics stock price performed over time
Intraday
1.88%
1 week
3.57%
1 month
7.49%
1 year
122.27%
YTD
7.57%
QTD
7.57%

Financial performance

How have Corcept Therapeutics's revenue and profit performed over time
Revenue
$356.03M
Gross profit
$350.27M
Operating income
$132.71M
Net income
$109.4M
Gross margin
98.4%
Net margin
30.7%
Corcept Therapeutics's operating income has increased by 31% YoY but it has decreased by 6% from the previous quarter
CORT's net income is up by 26% YoY but it is down by 4.1% QoQ
The gross profit is up by 25% year-on-year
The revenue rose by 25% year-on-year

Growth

What is Corcept Therapeutics's growth rate over time

Valuation

What is Corcept Therapeutics stock price valuation
P/E
29.62
P/B
6.64
P/S
9.15
EV/EBIT
24.43
EV/EBITDA
24.02
EV/Sales
9.1
The P/E is 87% more than the last 4 quarters average of 15.8 but 56% less than the 5-year quarterly average of 67.7
The EPS has grown by 25% year-on-year but it has declined by 4% since the previous quarter
The stock's price to book (P/B) is 70% more than its last 4 quarters average of 3.9 but 45% less than its 5-year quarterly average of 12.1
The company's equity rose by 46% YoY and by 8% QoQ
CORT's P/S is 87% above its last 4 quarters average of 4.9 and 9% above its 5-year quarterly average of 8.4
The revenue rose by 25% year-on-year

Efficiency

How efficient is Corcept Therapeutics business performance
CORT's ROIC is down by 16% since the previous quarter and by 15% year-on-year
The return on equity has declined by 13% since the previous quarter and by 13% year-on-year
CORT's return on assets is down by 12% since the previous quarter and by 11% year-on-year
The return on sales has declined by 7% since the previous quarter but it has grown by 4.8% year-on-year

Dividends

What is CORT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CORT.

Financial health

How did Corcept Therapeutics financials performed over time
The company's total assets rose by 46% YoY and by 7% QoQ
The quick ratio is up by 34% year-on-year and by 3.4% since the previous quarter
Corcept Therapeutics's debt is 99% lower than its equity
The company's equity rose by 46% YoY and by 8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.